Free tool
FAERS Monitor: Renflexis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761054 or its brand name (Renflexis, Infliximab-Abda). Reports on generic versions are filed under their own applications.
Reports
61,715
Serious
59,686
97% of reports
Hospitalization
21,938
Death reported
7,134
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use21,242
- condition aggravated13,192
- drug ineffective12,511
- intentional product use issue10,146
- arthralgia8,428
- fatigue6,811
- pain6,480
- inappropriate schedule of product administration5,922
- nausea5,656
- weight increased5,605
- headache5,467
- malaise5,372
- diarrhoea5,324
- rheumatoid arthritis5,190
- rash4,947
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 271 |
| 2005 | 759 |
| 2006 | 337 |
| 2007 | 524 |
| 2008 | 480 |
| 2009 | 722 |
| 2010 | 478 |
| 2011 | 404 |
| 2012 | 786 |
| 2013 | 258 |
| 2014 | 260 |
| 2015 | 387 |
| 2016 | 570 |
| 2017 | 882 |
| 2018 | 1,692 |
| 2019 | 3,614 |
| 2020 | 5,586 |
| 2021 | 4,852 |
| 2022 | 8,535 |
| 2023 | 8,837 |
| 2024 | 7,418 |
| 2025 | 8,932 |
| 2026 | 5,119 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,992,444 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional product use issueSignal | 10,146 | 44.5 | 43.7 | 383,122 |
| rheumatoid arthritisSignal | 5,190 | 16.3 | 15.8 | 71,392 |
| condition aggravatedSignal | 13,192 | 15.4 | 15.2 | 172,565 |
| inappropriate schedule of product administrationSignal | 5,922 | 11.5 | 11.3 | 55,632 |
| weight increasedSignal | 5,605 | 8.7 | 8.5 | 37,762 |
| off label useSignal | 21,242 | 8.4 | 8.4 | 142,010 |
| arthralgiaSignal | 8,428 | 7.0 | 6.9 | 43,567 |
| malaiseSignal | 5,372 | 4.2 | 4.1 | 13,280 |
| rashSignal | 4,947 | 3.9 | 3.8 | 10,770 |
| painSignal | 6,480 | 3.6 | 3.5 | 12,538 |
| drug ineffectiveSignal | 12,511 | 3.3 | 3.2 | 20,671 |
| fatigueSignal | 6,811 | 3.0 | 2.9 | 9,339 |
| headacheSignal | 5,467 | 3.0 | 2.9 | 7,392 |
| diarrhoeaSignal | 5,324 | 2.8 | 2.8 | 6,425 |
| nauseaSignal | 5,656 | 2.4 | 2.4 | 4,986 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.